최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of Korean biological nursing science, v.20 no.2, 2018년, pp.55 - 66
안수정 (연세대학교 대학원) , 최소영 (연세대학교 대학원) , 정혜정 (세브란스병원) , 추상희 (연세대학교 간호대학.김모임간호학연구소)
Purpose: Peripheral neuropathy is common among colorectal cancer (CRC) patients who undergo oxaliplatin-based (OXL) chemotherapy. A pharmacogenetic approach can be used to identify patients at high-risk of developing severe neuropathy. This type of approach can also help clinicians determine the bes...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
대장암의 표준 치료는 무엇이 있는가? | 옥살리플라틴(oxaliplatin)은 전이성 대장암에서 고식적 치료뿐만 아니라 수술 후 보조 항암요법으로 사용되고 있어 대장암의 표준치료로 알려져 있다. 그러나 옥살리플라틴의 사용은 급성 또는 만성으로 나타나는 말초신경병증(oxaliplatin-induced peripheral neuropathy, OXIPN)의 발현으로 제한되기도 한다. | |
급성 OXIPN과 만성 OXIPN의 차이는? | OXIPN은 급성과 만성으로 두 가지 다른 특성을 가진다. 급성 OXIPN은 가역적이며, 차가움과 연관된 감각이상으로 거의 모든 환자에게서 경련의 형태로 나타난다. 만성 OXIPN은 주로 장기간 지속되며 약물의 용량의존적(역치용량 500-600 mg/m 2 )이다[36]. OXIPN은 약물 투여에 영향을 주어 용량 감량 뿐만 아니라 치료 중단을 가져오며 증상의 지속은 삶의 질 저하에 심각한 영향을 미친다. | |
옥살리플라틴의 부작용은 어떠한 것이 있는가? | 그러나 옥살리플라틴의 사용은 급성 또는 만성으로 나타나는 말초신경병증(oxaliplatin-induced peripheral neuropathy, OXIPN)의 발현으로 제한되기도 한다. 급성 증상의 경우 항암제가 투여되는 동안 또는 직후 숨이 참(shortness of breath), 턱 경련(jaw spasm), 근육 경련(muscle cramps), 연하곤란(swallowing difficulties) 등의 증상 등이 나타난다[1]. 심한 급성 옥살리플라틴의 독성은 약 22%의 환자에서 치료 중단 또는 지연을 유발하는데 이는 환자의 예후에도 부정적인 영향을 미친다[2]. |
Argyriou A. Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics. 2015;3(2):187-197. http://doi.org/10.3390/toxics3020187
Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Management and Research. 2014;6:135-147. http://doi.org/10.2147/CMAR.S44261
Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncologica. 2007;46(8):1131-1137. http://doi.org/10.1080/02841860701355055
Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-20. http://doi.org/10.1097/NCC.0b013e31820251de
Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews. 2008;34(4):368-377. http://doi.org/10.1016/j.ctrv.2008.01.003
Chaudhary R, Singh B, Kumar M, Gakhar SK, Saini AK, Parmar VS, et al. Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. Drug Metabolism Reviews. 2015;47(3):281-290. http://doi.org/10.3109/03602532.2015.1047027
Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, et al. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis. Journal of the Peripheral Nervous System. 2015;20(1):15-23. http://doi.org/10.1111/jns.12110
Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. The Lancet Oncology. 2011;12(12):1151-1161. http://doi.org/10.1016/s1470-2045(11)70131-0
Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer. 2013;119(19):3570-3577. http://doi.org/10.1002/cncr.28234
Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. The Pharmacogenomics Journal. 2013;13(5):403-409. http://doi.org/10.1038/tpj.2012.31
Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study. Annals of Oncology. 2014;25(2):398-403. http://doi.org/10.1093/annonc/mdt546
Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemotherapy and Pharmacology. 2011;67(5):1179-1187. http://doi.org/10.1007/s00280-010-1466-y
Sereno M, Gutierrez-Gutierrez G, Rubio JM, Apellaniz-Ruiz M, Sanchez-Barroso L, Casado E, et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. 2017;17(1):63. http://doi.org/10.1186/s12885-016-3031-5
Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clincal Cancer Research. 2006;12(10):3050-3056. http://doi.org/10.1158/1078-0432.ccr-05-2076
Cortejoso L, Garcia MI, Garcia-Alfonso P, Gonzalez-Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemotherapy and Pharmacology. 2013;71(6):1463-1472. http://doi.org/10.1007/s00280-013-2145-6
Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828-2836. http://doi.org/10.1002/cncr.26614
Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemotherapy and Pharmacology. 2011;67(6):1323-1331. http://doi.org/10.1007/s00280-010-1425-7
McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology. 2010;28(20):3227-3233. http://doi.org/10.1200/jco.2009.21.7943
Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? European Journal of Neurology. 2010;17(7):963-968. http://doi.org/10.1111/j.1468-1331.2010.02966.x
Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, et al. Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clinical Cancer Research. 2007;13(21):6359-6368. http://doi.org/10.1158/1078-0432.ccr-07-0660
Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, et al. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. International Journal of Clinical Pharmacology and Therapeutics. 2013;51(6):475-481. http://doi.org/10.5414/CP201851
Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. International Journal of Clinical Pharmacology and Therapheutics. 2010;48(11):729-734.
Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, et al. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Annals of Oncology. 2016;27(6):1143-1148. http://doi.org/10.1093/annonc/mdw074
Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2009;100(7):1261-1266. http://doi.org/10.1111/j.1349-7006.2009.01186.x
Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis. British Journal of Cancer. 2010;102(6):987-994. http://doi.org/10.1038/sj.bjc.6605595
Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. Journal of Clinical Oncology. 2009;27(33):5519-5528. http://doi.org/10.1200/jco.2008.21.6283
Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British Journal of Cancer. 2008;99(7):1050-1055. http://doi.org/10.1038/sj.bjc.6604671
Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Journal of the National Cancer Institute. 2002;94(12):936-942.
Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, et al. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology Letters. 2013;6(3):648-654. http://doi.org/10.3892/ol.2013.1467
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of Clinical Oncology. 2007; 25(10):1247-1254. http://doi.org/10.1200/jco.2006.08.1844
Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2010;101(2):530-535. http://doi.org/10.1111/j.1349-7006.2009.01418.x
Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of Clinical Oncology. 2010;28(15):2556-2564. http://doi.org/10.1200/jco.2009.25.2106
Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology. 2009;77(3-4):254-256. http://doi.org/ 10.1159/000236049
Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer chemotherapy and pharmacology. 2013;71(4):843-851. http://doi.org/10.1007/s00280-013-2075-3
Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, et al. Associations between glutathione S-transferase Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer epidemiology. 2010;34(2):189-193. http://doi.org/10.1016/j.canep.2010.02.008
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(Suppl 4):iv45-54. http://doi.org/10.1093/neuonc/nos203
Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: Management of neuropathy in cancer. Journal of National Comprehensive Cancer Network. 2009;7(Suppl 5):S1-S26.
Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology. 2006;24(14): 2158-2163. http://doi.org/10.1200/jco.2006.06.5961
Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research. 2005;11(16):5878-5885. http://doi.org/10.1158/1078-0432.CCR-04-2618
Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, et al. Associations between UGT1A1* 6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemotherapy and Pharmacology. 2014;73(4):779-788. http://doi.org/10.1007/s00280-014-2405-0
Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, et al. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced nonsmall cell lung cancer. Cancer Chemotherapy and Pharmacology. 2009;64(5):917-924. http://doi.org/10.1007/s00280-009-0943-7
Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anti-Cancer Drugs. 2013;24(10):1069-1078. http://doi.org/10.1097/CAD.0000000000000002
Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: Chemotherapy-induced peripheral neuropathy. Methods in Molecular Biololgy Pharmacogenomics in Drug Discovery and Development. 2014;1175:301-322. http://doi.org/10.1007/978-1-4939-0956-8_12
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.